Genetic Technologies Ltd Asset Resilience Ratio
Genetic Technologies Ltd asset resilience ratio. Genetic Technologies Ltd (GTG) has an Asset Resilience Ratio of 0.30% as of June 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See operational self-sufficiency of Genetic Technologies Ltd to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Genetic Technologies Ltd (2002–2024)
Asset resilience ratio of Genetic Technologies Ltd from 2002 to 2024. This chart shows how Genetic Technologies Ltd's Asset Resilience Ratio has changed over time. Read GTG total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Genetic Technologies Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see total assets of Genetic Technologies Ltd.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | AU$0.00 | 0% |
| Short-term Investments | AU$18.79K | 0.3% |
| Total Liquid Assets | AU$18.79K | 0.30% |
Asset Resilience Insights
- Limited Liquidity: Genetic Technologies Ltd maintains only 0.30% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Genetic Technologies Ltd Industry Peers by Asset Resilience Ratio
Compare Genetic Technologies Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
ICON Public Limited Company
F:IJF |
Diagnostics & Research | 0.00% |
|
Guangzhou Kingmed Diagnostics Group Co Ltd
SHG:603882 |
Diagnostics & Research | 0.14% |
|
Vijaya Diagnostic Centre Limited
NSE:VIJAYA |
Diagnostics & Research | 15.15% |
|
Chemclin Diagnostics Co. Ltd. A
SHG:688468 |
Diagnostics & Research | 15.34% |
|
Healius Ltd
AU:HLS |
Diagnostics & Research | 0.06% |
|
INTERGRATED DIA.H DL 025
F:8I8 |
Diagnostics & Research | 7.34% |
|
Shanghai Rendu Biotechnology Co. Ltd. A
SHG:688193 |
Diagnostics & Research | 70.50% |
|
Scope Fluidics SA
WAR:SCP |
Diagnostics & Research | 16.51% |
Genetic Technologies Ltd Asset Resilience Ratio by Year (2002–2024)
Genetic Technologies Ltd asset resilience ratio by year from 2002 to 2024. The table below shows the annual Asset Resilience Ratio data for Genetic Technologies Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-06-30 | 0.30% | AU$18.79K ≈ $13.30K |
AU$6.19 Million ≈ $4.38 Million |
+0.19pp |
| 2023-06-30 | 0.12% | AU$17.44K ≈ $12.34K |
AU$14.86 Million ≈ $10.51 Million |
+0.05pp |
| 2022-06-30 | 0.06% | AU$13.26K ≈ $9.38K |
AU$20.80 Million ≈ $14.72 Million |
+0.06pp |
| 2021-06-30 | 0.01% | AU$1.86K ≈ $1.31K |
AU$22.97 Million ≈ $16.25 Million |
0.00pp |
| 2020-06-30 | 0.01% | AU$2.02K ≈ $1.43K |
AU$15.63 Million ≈ $11.06 Million |
-1.62pp |
| 2019-06-30 | 1.64% | AU$53.46K ≈ $37.82K |
AU$3.27 Million ≈ $2.31 Million |
+1.58pp |
| 2018-06-30 | 0.06% | AU$3.50K ≈ $2.48K |
AU$6.17 Million ≈ $4.36 Million |
+0.03pp |
| 2017-06-30 | 0.03% | AU$3.38K ≈ $2.39K |
AU$12.11 Million ≈ $8.57 Million |
0.00pp |
| 2016-06-30 | 0.03% | AU$4.21K ≈ $2.98K |
AU$13.29 Million ≈ $9.40 Million |
+0.01pp |
| 2015-06-30 | 0.02% | AU$3.59K ≈ $2.54K |
AU$20.72 Million ≈ $14.66 Million |
-0.03pp |
| 2014-06-30 | 0.04% | AU$2.95K ≈ $2.09K |
AU$6.73 Million ≈ $4.76 Million |
-2.47pp |
| 2013-06-30 | 2.52% | AU$209.30K ≈ $148.09K |
AU$8.32 Million ≈ $5.89 Million |
+2.41pp |
| 2012-06-30 | 0.11% | AU$17.46K ≈ $12.35K |
AU$16.44 Million ≈ $11.63 Million |
+0.08pp |
| 2011-06-30 | 0.03% | AU$2.65K ≈ $1.87K |
AU$8.92 Million ≈ $6.31 Million |
-0.84pp |
| 2010-06-30 | 0.87% | AU$71.66K ≈ $50.70K |
AU$8.28 Million ≈ $5.86 Million |
+0.86pp |
| 2009-06-30 | 0.00% | AU$200.00 ≈ $141.51 |
AU$22.28 Million ≈ $15.76 Million |
-2.15pp |
| 2008-06-30 | 2.15% | AU$519.12K ≈ $367.31K |
AU$24.15 Million ≈ $17.09 Million |
+1.78pp |
| 2007-06-30 | 0.37% | AU$77.00K ≈ $54.48K |
AU$20.95 Million ≈ $14.82 Million |
+0.07pp |
| 2005-06-30 | 0.30% | AU$88.00K ≈ $62.27K |
AU$29.26 Million ≈ $20.71 Million |
+0.13pp |
| 2004-06-30 | 0.17% | AU$38.44K ≈ $27.20K |
AU$22.39 Million ≈ $15.84 Million |
-0.69pp |
| 2003-06-30 | 0.86% | AU$261.58K ≈ $185.09K |
AU$30.25 Million ≈ $21.40 Million |
+0.65pp |
| 2002-06-30 | 0.21% | AU$70.00K ≈ $49.53K |
AU$33.00 Million ≈ $23.35 Million |
-- |
About Genetic Technologies Ltd
Genetic Technologies Limited, a molecular diagnostics company, engages in the provision of predictive genetic testing and risk assessment tools to help physicians manage people's health in the America, Canada, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company operates through EasyDNA, AffinityDNA, and GeneType/Corporate segments. It offers BREVAGenplus, a clinicall… Read more